Resona Asset Management Co. Ltd. Sells 25,120 Shares of Pfizer Inc. $PFE

Resona Asset Management Co. Ltd. trimmed its stake in shares of Pfizer Inc. (NYSE:PFE – Free Report) by 1.4% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,781,489 shares of the biopharmaceutical company’s stock after selling 25,120 shares during the quarter. Resona Asset Management Co. Ltd.’s holdings in Pfizer were worth $50,879,000 at the end of the most recent quarter.

Several other large investors also recently bought and sold shares of PFE. BlackRock Inc. increased its position in shares of Pfizer by 6.3% in the 2nd quarter. BlackRock Inc. now owns 529,670,433 shares of the biopharmaceutical company’s stock valued at $12,754,464,000 after purchasing an additional 31,412,883 shares during the last quarter. State Street Corp raised its holdings in shares of Pfizer by 1.8% in the 2nd quarter. State Street Corp now owns 307,090,897 shares of the biopharmaceutical company’s stock valued at $7,394,749,000 after purchasing an additional 5,501,032 shares in the last quarter. Bank of New York Mellon Corp lifted its position in shares of Pfizer by 7.4% during the 2nd quarter. Bank of New York Mellon Corp now owns 57,879,546 shares of the biopharmaceutical company’s stock worth $1,393,739,000 after purchasing an additional 3,999,646 shares during the last quarter. Bank of America Corp DE purchased a new stake in shares of Pfizer during the 2nd quarter worth $1,049,602,000. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its position in shares of Pfizer by 4.7% during the 2nd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 36,157,306 shares of the biopharmaceutical company’s stock worth $870,668,000 after purchasing an additional 1,634,374 shares during the last quarter. Hedge funds and other institutional investors own 68.36% of the company’s stock.

Analyst Ratings Changes

A number of analysts have weighed in on the company. HSBC raised their price target on Pfizer from $28.00 to $30.00 and gave the company a “hold” rating in a research note on Thursday, September 10th. DZ Bank cut Pfizer from a “buy” rating to a “hold” rating in a research report on Friday, November 6th. Cantor Fitzgerald increased their price objective on Pfizer from $27.00 to $28.00 and gave the company a “neutral” rating in a report on Thursday, October 8th. Argus set a $40.00 price objective on Pfizer in a report on Wednesday, November 4th. Finally, Sanford C. Bernstein reissued a “market perform” rating and set a $29.00 target price on shares of Pfizer in a research report on Thursday, November 12th. Six investment analysts have rated the stock with a Buy rating, fourteen have issued a Hold rating and two have given a Sell rating to the company’s stock. Based on data from MarketBeat.com, Pfizer currently has an average rating of “Hold” and an average price target of $30.32.

Read Our Latest Stock Analysis on Pfizer

More Pfizer News

Investors following PFE have been watching these news items:

  • Positive Sentiment: A recent analysis said Pfizer’s launched and acquired products grew 32% in the third quarter, suggesting newer medicines are gaining traction and could help offset pressure on older products and COVID-related revenue. Article: Pfizer's Launched and Acquired Drugs Grew 32% in Q3
  • Neutral Sentiment: Pfizer also reported updates to clinical studies, including an RSV booster study in older adults and a Phase 3 study of berobenatide. The entries provide no trial results, so they offer limited evidence of near-term commercial impact. Article: Pfizer Advances RSV Booster Study in Older Adults
  • Negative Sentiment: Technical indicators cited in a market update showed weak near-term momentum, with daily signals at “Strong Sell” and hourly signals at “Sell.” That may weigh on sentiment even as Pfizer pursues pipeline growth. Article: Pfizer near-term support and resistance levels

Pfizer Stock Down 0.5%

Pfizer stock opened at $27.41 on Friday. The stock has a 50 day moving average of $28.82 and a two-hundred day moving average of $27.03. Pfizer Inc. has a twelve month low of $23.62 and a twelve month high of $31.44. The stock has a market capitalization of $156.25 billion, a price-to-earnings ratio of 39.16, a PEG ratio of 1.90 and a beta of 0.31. The company has a current ratio of 1.42, a quick ratio of 1.10 and a debt-to-equity ratio of 0.67.

Pfizer (NYSE:PFE – Get Free Report) last released its earnings results on Tuesday, November 3rd. The biopharmaceutical company reported $0.87 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.74 by $0.13. Pfizer had a return on equity of 19.88% and a net margin of 6.34%. The business had revenue of $16.58 billion for the quarter, compared to analyst estimates of $15.85 billion. During the same quarter in the previous year, the company posted $0.87 earnings per share. The company’s revenue for the quarter was down .4% compared to the same quarter last year. As a group, research analysts expect that Pfizer Inc. will post 3.04 earnings per share for the current year.

Pfizer Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Monday, December 7th. Shareholders of record on Friday, November 6th will be paid a $0.43 dividend. This represents a $1.72 annualized dividend and a yield of 6.3%. The ex-dividend date of this dividend is Friday, November 6th. Pfizer’s payout ratio is currently 245.71%.

Pfizer Company Profile

(Free Report)

Pfizer Inc. is a global biopharmaceutical company that researches, develops, manufactures and commercializes prescription medicines and vaccines. Its work spans areas including oncology, vaccines, internal medicine, inflammation and immunology, rare diseases, and infectious diseases. The company’s products include the Prevnar family of vaccines and medicines such as Eliquis, which it commercializes with Bristol Myers Squibb, and Paxlovid. Pfizer also developed the Comirnaty COVID-19 vaccine with BioNTech.

Featured Stories

Institutional Ownership by Quarter for Pfizer (NYSE:PFE)

Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.